Butterfly Network Inc., a digital health company specializing in handheld, whole-body ultrasound technology, announced that the European Commission has initiated the review and stakeholder consultation period for the company's request to revoke a specific exemption within the European Commission's Restriction of Hazardous Substances (RoHS) Directive. This exemption historically allowed the use of lead in single crystal piezoelectric materials for ultrasonic transducers. The Oeko-Institut has been appointed to conduct a technical assessment and third-party evaluation of this request. The stakeholder consultation will run from June 6, 2025, to August 1, 2025. A recommendation is expected by Q2 of 2026, with potential legal changes to follow 12 to 18 months after final adoption. Butterfly Network is optimistic about aligning ultrasound manufacturing with the EU's sustainability goals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.